Association of Fibroblast Growth Factor-23 Levels and Angiotensin-Converting Enzyme Inhibition in Chronic Systolic Heart Failure

JACC: Heart Failure

Volumn 3, Issue 10, 2015, Pages 829-839

  Wohlfahrt, Peter ^a,b   Melenovsky, Vojtech ^a   Kotrc, Martin ^a   Benes, Jan ^a   Jabor, Antonin ^a,b   Franekova, Janka ^a,b   Lemaire, Sophia ^c   Kautzner, Josef ^a   Jarolim, Petr ^c  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Adverse events; Angiotensin converting enzyme inhibitor; Fibroblast growth factor 23; Heart failure; Outcome

Indexed keywords

ALKALINE PHOSPHATASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBROBLAST GROWTH FACTOR 23; BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CAVA VEIN; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DEATH; DEVICE THERAPY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME INHIBITION; FEMALE; HEART TRANSPLANTATION; HUMAN; KIDNEY BLOOD FLOW; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC HEART FAILURE; TRICUSPID VALVE REGURGITATION; VEIN DILATATION; VENTRICULAR ASSIST DEVICE; AGED; BLOOD; CHRONIC DISEASE; COHORT ANALYSIS; COMPLICATION; DOPPLER ECHOCARDIOGRAPHY; HEART FAILURE, SYSTOLIC; KAPLAN MEIER METHOD; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TEST; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PHOTON ABSORPTIOMETRY; PREDICTIVE VALUE; PROCEDURES; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ABSORPTIOMETRY, PHOTON; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOMARKERS; CHRONIC DISEASE; COHORT STUDIES; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; FIBROBLAST GROWTH FACTORS; HEART FAILURE, SYSTOLIC; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84943418755     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2015.05.012     Document Type: Article

References (40)

1. Shimada T., Kakitani M., Yamazaki Y., et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004, 113:561-568.
2. Poelzl G., Trenkler C., Kliebhan J., et al. FGF23 is associated with disease severity and prognosis in chronic heart failure. Eur J Clin Invest 2014, 44:1150-1158.
3. Faul C., Amaral A.P., Oskouei B., et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011, 121:4393-4408.
4. Gutierrez O.M., Januzzi J.L., Isakova T., et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009, 119:2545-2552.
5. Ix J.H., Shlipak M.G., Wassel C.L., Whooley M.A. Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study. Nephrol Dial Transplant 2010, 25:993-997.
6. Kendrick J., Cheung A.K., Kaufman J.S., et al. FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol 2011, 22:1913-1922.
7. Parker B.D., Schurgers L.J., Brandenburg V.M., et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med 2010, 152:640-648.
8. Kestenbaum B., Sachs M.C., Hoofnagle A.N., et al. Fibroblast growth factor-23 and cardiovascular disease in the general population: the Multi-Ethnic Study of Atherosclerosis. Circ Heart Fail 2014, 7:409-417.
9. Udell J.A., Morrow D.A., Jarolim P., et al. Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease. J Am Coll Cardiol 2014, 63:2421-2428.
10. Plischke M., Neuhold S., Adlbrecht C., et al. Inorganic phosphate and FGF-23 predict outcome in stable systolic heart failure. Eur J Clin Invest 2012, 42:649-656.
11. Shane E., Mancini D., Aaronson K., et al. Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure. Am J Med 1997, 103:197-207.
12. Wolf M. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int 2012, 82:737-747.
13. Kitagawa M., Sugiyama H., Morinaga H., et al. A decreased level of serum soluble Klotho is an independent biomarker associated with arterial stiffness in patients with chronic kidney disease. PloS One 2013, 8:e56695.
14. Kuro-o M., Matsumura Y., Aizawa H., et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997, 390:45-51.
15. de Borst M.H., Vervloet M.G., ter Wee P.M., Navis G. Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease. J Am Soc Nephrol 2011, 22:1603-1609.
16. Six I., Okazaki H., Gross P., et al. Direct, acute effects of Klotho and FGF23 on vascular smooth muscle and endothelium. PloS One 2014, 9:e93423.
17. Kovesdy C.P., Quarles L.D. The role of fibroblast growth factor-23 in cardiorenal syndrome. Nephron Clin Pract 2013, 123:194-201.
18. Seiler S., Rogacev K.S., Roth H.J., et al. Associations of FGF-23 and sKlotho with cardiovascular outcomes among patients with CKD stages 2-4. Clin J Am Soc Nephrol 2014, 9:1049-1058.
19. Stubbs J.R., He N., Idiculla A., et al. Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease. J Bone Miner Res 2012, 27:38-46.
20. Tokmakova M.P., Skali H., Kenchaiah S., et al. Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study. Circulation 2004, 110:3667-3673.
21. Solomon S.D., Rice M.M., Jablonski K.A., et al. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation 2006, 114:26-31.
22. Melenovsky V., Kotrc M., Borlaug B.A., et al. Relationships between right ventricular function, body composition, and prognosis in advanced heart failure. J Am Coll Cardiol 2013, 62:1660-1670.
23. Levey A.S., Stevens L.A., Schmid C.H., et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009, 150:604-612.
24. DeLong E.R., DeLong D.M., Clarke-Pearson D.L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988, 44:837-845.
25. Pencina M.J., D'Agostino R.B., D'Agostino R.B., Vasan R.S. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Statistics in Medicine 2008, 27:157-172.
26. Gruson D., Lepoutre T., Ketelslegers J.M., Cumps J., Ahn S.A., Rousseau M.F. C-terminal FGF23 is a strong predictor of survival in systolic heart failure. Peptides 2012, 37:258-262.
27. Xie J., Cha S.K., An S.W., Kuro-O M., Birnbaumer L., Huang C.L. Cardioprotection by Klotho through downregulation of TRPC6 channels in the mouse heart. Nature Commun 2012, 3:1238.
28. Agarwal I., Ide N., Ix J.H., et al. Fibroblast growth factor-23 and cardiac structure and function. J Am Heart Assoc 2014, 3:e000584.
29. Schierbeck L.L., Jensen T.S., Bang U., Jensen G., Kober L., Jensen J.E. Parathyroid hormone and vitamin D-markers for cardiovascular and all cause mortality in heart failure. Eur J Heart Fail 2011, 13:626-632.
30. Witham M.D., Crighton L.J., Gillespie N.D., Struthers A.D., McMurdo M.E. The effects of vitamin D supplementation on physical function and quality of life in older patients with heart failure: a randomized controlled trial. Circ Heart Fail 2010, 3:195-201.
31. Boxer R.S., Kenny A.M., Schmotzer B.J., Vest M., Fiutem J.J., Pina I.L. A randomized controlled trial of high dose vitamin D3 in patients with heart failure. J Am Coll Cardiol HF 2013, 1:84-90.
32. Arnlov J., Carlsson A.C., Sundstrom J., et al. Serum FGF23 and risk of cardiovascular events in relation to mineral metabolism and cardiovascular pathology. Clin J Am Soc Nephrol 2013, 8:781-786.
33. Terrovitis J., Zotos P., Kaldara E., et al. Bone mass loss in chronic heart failure is associated with secondary hyperparathyroidism and has prognostic significance. Eur J Heart Fail 2012, 14:326-332.
34. Jovanovich A., Buzkova P., Chonchol M., et al. Fibroblast growth factor 23, bone mineral density, and risk of hip fracture among older adults: the cardiovascular health study. J Clin Endocrinol Metab 2013, 98:3323-3331.
35. Urena Torres P., Friedlander G., de Vernejoul M.C., Silve C., Prie D. Bone mass does not correlate with the serum fibroblast growth factor 23 in hemodialysis patients. Kidney Int 2008, 73:102-107.
36. Smith G.L., Lichtman J.H., Bracken M.B., et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol 2006, 47:1987-1996.
37. Damman K., Navis G., Voors A.A., et al. Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J Card Fail 2007, 13:599-608.
38. van Deursen V.M., Damman K., Voors A.A., et al. Prognostic value of plasma neutrophil gelatinase-associated lipocalin for mortality in patients with heart failure. Circ Heart Fail 2014, 7:35-42.
39. Damman K., Masson S., Hillege H.L., et al. Clinical outcome of renal tubular damage in chronic heart failure. Eur Heart J 2011, 32:2705-2712.
40. Nymo S.H., Ueland T., Askevold E.T., et al. The association between neutrophil gelatinase-associated lipocalin and clinical outcome in chronic heart failure: results from CORONA*. J Intern Med 2012, 271:436-443.